Immuno-Oncology Conference (I-O) 360°
Meet with Q2 Solutions and IQVIA at the 2020 I-O 360° Conference, booths #10 and #11, and learn how we can help you ensure that the right drug is used to treat the right patient at the right time
About This EventI-O 360˚ brings together stakeholders in the science and business communities interested in data-driven advancements in immuno-oncology to fight a wider range of cancers.
Q2 Solutions’ industry leading central lab services are closely tailored to power immuno-oncology studies across the development continuum. We can help leverage latest cancer research and precision medicine industry findings, and design smarter clinical trials through a range of genomic services.
Be sure to attend the Discovery & Preclinical Science Plenary Session to hear our presentation given by Patrick Hurban Ph.D.
- Title: Immune Landscape Signatures for Tumor Microenvironment Characterization and Therapy Response
- Date & time: Wednesday, February 26 at 11:10am
We look forward to meeting you at booths #10 and 11 in New York City.
Patrick Hurban, Ph.D. is senior director and global head of Translational Genomics at Q2 Solutions. In this role, he is responsible for the identification and implementation of new genomic capabilities, encompassing bioinformatics and wet-laboratory methods, as well as the development and validation of genomic assays to support research and clinical programs. These include broad-based screening assays, such as exome and RNA sequencing, to highly focused expression, genotyping and sequencing assay panels that target a smaller number of genes.
Dr. Hurban has more than 25 years of experience in molecular genetics, including more than 18 years in positions of increasing responsibility in high-profile genomics-focused organizations. His research interests have focused on the genetic control of gene expression and have spanned diverse fields such as toxicology, developmental, and cancer biology.
Following a Bachelor’s degree in Biology from the University of North Carolina at Chapel Hill, he earned his Ph.D. in Human Genetics from the University of Utah in Salt Lake City before serving as a postdoctoral research fellow of the American Cancer Society in the Department of Developmental Biology at Stanford University.